WELCOME TO The Biotechnology REPORT
Tiziana Life Sciences
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
BioSpace | February 20, 2020
Kane Biotech Inc. (TSX-V:KNE) (the “Corporation” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, today announced that it has appointed Jean Gauvin, DVM, as its Chief Veterinary Officer (“CVO”), effective immediately. In the newly-created position of CVO, Dr. Gauvin will serve as a liaison between Kane Biotech and industry, guide the K...
Biocytogen | September 25, 2020
In August, Beijing Biocytogen Biotechnology Co., Ltd. ("Biocytogen") announced acquisition of Eucure Biopharma, which established Biocytogen as a clinical stage company. Now, Biocytogen is pleased to announce completion of series D1 Funding, successfully raising 142 million dollars (USD) meant to further secure the implementation of Project Integrum.Project Integrum is a humanitarian effort to discover, develop, and bring to market novel therapeutic antibody candidates against al...
Express Healthcare | April 02, 2020
The investment in MedGenome will seek to capitalise on favourable dynamics in both domestic, international markets for genetic diagnostics. MedGenome recently announced an investment of $55m led by LeapFrog Investments. Existing investors Sofina and Sequoia also participated in the round. Sam Santhosh, CEO and Founder, MedGenome said, “Genomics and personalised medicine are the future of healthcare, but emerging markets remain significantly under-penetrated. As the largest player in India ...
CELL AND GENE THERAPY
Mekonos, Inc. | November 10, 2021
Mekonos, a biotech company building the future of cell therapies on a chip, has raised $25M in an oversubscribed Series A round co-led by Reimagined Ventures, Fiscus Ventures, and PEAK6 Strategic Capital, a division of PEAK6 Investments. New institutional and strategic investors, including Section 32, Sands Capital, TDK Ventures, and the venture arm of Debiopharm, and previous investors, including Novartis Pharma AG (dRx Capital) and Elementum Ventures, also joined in the funding round that will...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE